让生命更精彩,让生活更美好


       陕西慧康生物科技有限责任公司,成立于2001年,专注于生物科技前沿领域“活性蛋白与多肽”生物再生工程与应用科技研究,科技人员占比达37% 以上,是一家生物科技研发平台公司。公司经营范围涵盖一类新药、医疗器械、生物高科护肤品等。

Shaanxi HuiKang Bio-Tech Co., Ltd., founded in 2001, is a biotechnology R&D platform company focusing on the biological regeneration engineering and applied science and technology research of "active proteins and peptides" in the frontier field of biotechnology. The proportion of scientific and technological personnel accounts for more than 37%. The business scope covers Class I New Drug, medical devices, biological high-tech skin care products, etc.

 

       2010年,公司成立慧康研究院,先后投入科研经费近亿元,启动并开展了基因工程、细胞工程领域的研究,全面进军生物医药产业。2019年投入使用的慧康生物科技产业园,作为全新的研发生产基地,占地42亩,总建筑面积6.5万平方米。

In 2010, the company established HuiKang Research Institute, successively invested nearly CNY100 million in scientific research, started and carried out research in the fields of genetic engineering and cell engineering, and comprehensively entered the biomedical industry. Huikang Biotechnology Industrial Park, which was put into use in 2019, as a new R & D and production base, covers an area of 42 Mu and a total construction area of 65,000 square meters.



       目前,陕西慧康生物拥有一支专业的研发团队,包括行业精英、知名大学教授等在内70余名专家骨干。团队长期与澳大利亚、韩国等海外生物学专家学者保持交流与合作。慧康生物研发中心是西北大学生命科学教学实习基地,并与其联合设立研发中心;同时作为陕西科技大学食品与生物工程学院产学研合作基地,于2017年挂牌成为西安市博士后创新基地、西安市人才工作创新试验基地、西安市活性蛋白与多肽工程技术研究中心。

At present, HuiKang Bio-Tech has a professional scientific research team with more than 70 experts, including industry elites and distinguished university professors. The team has maintained long-term exchanges and cooperation with oversea biological experts and scholars from Australia and Korea.HuiKang Bio-Tech R&D Center is the life science Teaching Practice Base of Northwest University, and jointly established R & D center with it; At the same time, The R&D center is also the Practice Base of Northwest University and Shaanxi University of Science and Technology. In 2017, the honors of Xi'an Post-doctoral Innovation Base, Xi'an Talent Work Innovation Experimental Base, and Xi'an Active Protein and Peptides Engineering Center were successively granted to R&D center.



       截止2022年10月底,慧康集团旗下子公司共有134项专利,其中国家发明专利65项、外观专利17项、实用新型专利25项、中国香港专利12项、国际专利15项;现有国家I类新药1项,医疗器械2项,西安市博士后创新基地项目3项,重点科研项目13项。《镁合金-重组人源胶原复合膜的制备与测试》获教育部国家重点实验室项目资助,《先导多肽筛选中试共享服务平台》以及《重组人溶菌酶滴眼液》被评为陕西省科技厅重点研发项目,《六胜肽产业化项目》被评为西安市科技进步奖。六胜肽科研成果论文刊登在美国《I&EC Research》杂志的封面,重组人源胶原蛋白以及胶原海绵研究成果刊登在《International Journal of Biological Macromolecules》杂志。

By the end of June 2022, Huikang group had 134 patents, including 65 national invention patents, 17 appearance patents, 25 utility model patents, 8 Hong Kong patents and 14 international patents; At present, there are 1 national class I new drug, 2 medical devices, 3 Xi'an Post Doctoral innovation base projects and 13 key scientific research projects. The preparation and testing of magnesium alloy recombinant human collagen composite membrane was supported by the National Key Laboratory Project of the Ministry of education. The pilot peptide screening pilot test sharing service platform and recombinant human lysozyme eye drops were rated as key R & D projects of Shaanxi Provincial Science and technology department. The Liusheng peptide industrialization project was rated as Xi'an Science and technology progress award. The research results of Liusheng peptide were published on the cover of i&ec research, and the research results of recombinant human collagen and collagen sponge were published in the International Journal of biological macrocells.